Compare UCTT & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UCTT | TNGX |
|---|---|---|
| Founded | 1991 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.5B |
| IPO Year | 2004 | 2020 |
| Metric | UCTT | TNGX |
|---|---|---|
| Price | $86.11 | $29.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $97.33 | $21.78 |
| AVG Volume (30 Days) | 1.4M | ★ 2.2M |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,734,500,000.00 | $62,384,000.00 |
| Revenue This Year | $19.18 | N/A |
| Revenue Next Year | $17.36 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $21.49 | $6.21 |
| 52 Week High | $144.22 | $34.39 |
| Indicator | UCTT | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Ultra Clean Holdings Inc, through its subsidiaries, manufactures and supplies production tools, modules, and subsystems for the semiconductor capital equipment industry. The product includes precision robotic solutions, gas delivery systems, and a variety of industrial and automation production equipment products; subsystems include wafer cleaning subsystems, chemical delivery modules, top-plate assemblies, frame assemblies, and process modules. Its customer base includes firms in the semiconductor capital equipment industry, medical, energy, industrial, flat panel, and research equipment industries. It has two segments: Products and Services. Its principal markets are the Americas, Asia Pacific, and EMEA.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.